Filgrastim
- Generic Name
- Filgrastim
- Brand Names
- Accofil, Granix, Grastofil, Neupogen, Nivestim, Nivestym, Ratiograstim, Releuko, Zarxio, Zarzio, Filgrastim Hexal, Tevagrastim
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 121181-53-1
- Unique Ingredient Identifier
- PVI5M0M1GW
- Background
Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in E. Coli. Human G...
- Indication
Filgrastim is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever.
...
- Associated Conditions
- Congenital neutropenia, Cyclic neutropenia, Febrile Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Idiopathic neutropenia, Infection, Neutropenia
- Associated Therapies
- Mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis therapy
G-CSF Treatment for Amyotrophic Lateral Sclerosis: A RCT Study Assessing Clinical Response
- Conditions
- Interventions
- First Posted Date
- 2006-11-09
- Last Posted Date
- 2007-11-28
- Lead Sponsor
- Peking University
- Target Recruit Count
- 40
- Registration Number
- NCT00397423
- Locations
- 🇨🇳
Dongsheng Fan, Beijing, Beijing, China
Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair
- Conditions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- University of Ottawa
- Target Recruit Count
- 86
- Registration Number
- NCT00394498
- Locations
- 🇨🇦
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 379
- Registration Number
- NCT00392327
- Locations
- 🇺🇸
Inova Fairfax Hospital, Falls Church, Virginia, United States
🇺🇸Bronson Methodist Hospital, Kalamazoo, Michigan, United States
🇵🇷University Pediatric Hospital, San Juan, Puerto Rico
Busulfan Monotherapy as Conditioning for Autologous Hematopoietic Progenitor Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 3
- Registration Number
- NCT00363467
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2017-12-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 102
- Registration Number
- NCT00349778
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: EtoposideBiological: FilgrastimOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentDrug: Leucovorin CalciumDrug: ThiotepaDrug: MethotrexateDrug: Vincristine Sulfate
- First Posted Date
- 2006-06-12
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 91
- Registration Number
- NCT00336024
- Locations
- 🇺🇸
Tulane University School of Medicine, New Orleans, Louisiana, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
🇺🇸NYU Langone Hospital - Long Island, Mineola, New York, United States
Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 29
- Registration Number
- NCT00334815
- Locations
- 🇺🇸
Ballad Health Cancer Care - Norton, Norton, Virginia, United States
🇺🇸Providence Hospital, Mobile, Alabama, United States
🇺🇸Saint Bernards Regional Medical Center, Jonesboro, Arkansas, United States
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 342
- Registration Number
- NCT00303719
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2020-09-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 55
- Registration Number
- NCT00290433
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
- First Posted Date
- 2006-02-13
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 43
- Registration Number
- NCT00290628
- Locations
- 🇺🇸
University of Minnesota Cancer Center, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.